Description

CJC-1295 without DAC, commonly referred to as Modified GRF (1-29), is a synthetic peptide derived from growth hormone-releasing hormone (GHRH). The peptide contains 29 amino acids and was developed to replicate the biologically active portion of the natural GHRH molecule.

This peptide represents a modified version of the original GRF (1-29) fragment, with four substituted amino acids designed to improve stability and resistance to enzymatic degradation. Unlike the DAC version, CJC-1295 without DAC does not include a Drug Affinity Complex, which is sometimes added to significantly extend a peptide’s half-life.

Research into growth hormone–releasing fragments dates back to the early 1980s, when scientists proposed that the first 29 amino acids of the natural 44-amino-acid GHRH molecule could retain much of the biological activity of the full peptide. However, early synthetic fragments were found to have very short half-lives, which led to the development of modified and stabilized versions such as CJC-1295 (No DAC).

Overview

CJC-1295 without DAC, also known as tetra-substituted GRF (1-29), is a synthetic peptide studied for its interaction with GHRH receptors and its potential role in growth hormone signaling pathways. The peptide is designed using the minimal sequence of amino acids believed to be required for binding to these receptors.

Compared with the original GRF (1-29), CJC-1295 without DAC includes four specific amino acid substitutions intended to improve molecular stability and reduce enzymatic breakdown, particularly from enzymes such as dipeptidyl peptidase-4 (DPP-4).

These structural modifications include:

• Position 2: L-alanine replaced with D-alanine, which may increase resistance to enzymatic degradation.

• Position 8: Asparagine replaced with glutamine, potentially reducing molecular instability associated with asparagine residues.

• Position 15: Glycine replaced with alanine, which has been suggested to enhance peptide activity.

• Position 27: Methionine replaced with leucine, a modification intended to help prevent methionine oxidation.

Because of these substitutions, CJC-1295 without DAC has been investigated in research settings for its potential influence on growth hormone release and endocrine signaling pathways. Ongoing studies continue to explore the peptide’s biological mechanisms and stability characteristics in laboratory environments.

Reference

https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295

• • • • • • • • • • • • • • • PLEASE READ • • • • • • • • • • • • • • •

RESEARCH USE ONLY DISCLAIMER AND LIMITATION OF LIABILITY

All articles, materials, content, and product-related information made available on this website are provided strictly for informational and educational purposes only and shall not be construed as medical, pharmaceutical, clinical, or therapeutic advice, nor as a representation of safety or efficacy for any human or animal use.

These products are not drugs, pharmaceuticals, biologics, medical devices, dietary supplements, food products, or cosmetics, and they have not been evaluated, approved, or authorized by the United States Food and Drug Administration (FDA) or any other regulatory authority for human or animal use.

The Company reserves all rights and expressly disclaims any liability arising from misuse, improper handling, or unauthorized application of its products.